Fresenius Kabi AG

10/01/2026 | Press release | Distributed by Public on 09/30/2026 23:33

Fresenius acquires remaining 45% of mAbxience, taking full ownership of its biosimilars platform

Building on a successful partnership since 2022, Fresenius has completed the acquisition of mAbxience. Together, the companies will strengthen development, manufacturing and commercial capabilities to help expand access to high-quality biosimilars for patients worldwide.

Fresenius Kabi AG published this content on October 01, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 01, 2026 at 05:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]